Phase I/II Study of FR104 First Administration In Patient With Renal Transplantation: FIRsT Study

Phase 1/2 Completed 10 enrolled Nantes University Hospital OSE Immunotherapeutics · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the safety, tolerability, pharmacokinetics (PK) of FR104 as well as its potential clinical effect on acute rejection prophylaxis and renal function in a de novo renal transplant population receiving an allograft from standard criteria donors.

Timeline

Start: 2021-06-28
Primary completion: 2025-04-14
Completion: 2025-04-14

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	pegrizeprument	Monoclonal antibody	—	—

Indications

No indication recorded.